Skip to main content
OpenTrials
Completed

NCT Number: NCT01435278

Efficacy and Safety of Glucosanol in Maintaining Body Weight

To date, there is no clinical evidence on the efficacy and safety of Glucosanol in maintaining weight loss beyond the study duration of 12 weeks. The rationale for this open-label study is to assess the efficacy in preventing regain of loss body weight and safety of Glucosanol in subjects who are overweight or obese over a longer period after the initial weight loss.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Barbara Grube, MD

Berlin, Germany

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Previously enrolled in, complied with, and completed the INQ/K/003411 (Glucosanol weight loss) study, with weight loss of at least 3% of baseline body weight
  • Age 18 to 60 years at the time of inclusion into the INQ/K/003411 study
  • BMI between 25-35 at the time of inclusion into the INQ/K/003411 study
  • Expressed desire for weight maintenance
  • Accustomed to 3 main meals per day
  • Commitment to avoid the use of other weight loss products during study
  • Females' agreement to use appropriate birth control methods during the active study period
  • Subject declares in writing his/her consent to participate, understands requirements of the study and is willing to comply

Exclusion criteria

  • Known sensitivity to the ingredients of the device (Phaseolus vulgaris or members of the Fabaceae family)
  • History of diabetes mellitus • Fasting blood glucose more than 7 mmol/L
  • History or clinical signs of endocrine disorders which may influence body weight (e.g. Cushing's disease, thyroid gland disorders)
  • Clinically relevant excursions of safety parameter
  • Current use of anti-depressants
  • Presence of acute or chronic gastrointestinal disease (e.g. IBD, coeliac disease, pancreatitis)
  • Uncontrolled hypertension (more than 160/110 mm Hg)
  • Stenosis in the GI tract
  • Bariatric surgery
  • Abdominal surgery within the last 6 months prior to enrollment
  • History of eating disorders like bulimia, anorexia nervosa within the past 12 months
  • Other serious organ or systemic diseases such as cancer
  • Any medication that could influence GI functions such as antibiotics, laxatives, opioids, glucocorticoids, anticholinergics, or anti-diarrheals
  • Pregnancy or nursing
  • Any medication or use of products for the treatment of obesity (e.g. Orlistat, other fatbinder, carb/starch blocker, fatburner, satiety products etc.)
  • More than 3 hours strenuous sport activity per week
  • History of abuse of drugs, alcohol or medication
  • Smoking cessation within 6 months prior to enrolment
  • Inability to comply due to language difficulties
  • Presence of other factor(s) that, in the investigator's judgement, should preclude subject participation

Treatment and study plan

Glucosanol

Device

2 tablets taken 3 times a day.

Primary outcomes

  1. Body weight

    Time frame: 24 weeks

    Measured in kg using a calibrated scale

Secondary outcomes

  1. Waist and hip circumference (cm)

    Time frame: 24 weeks

    Changes from baseline to end of study

  2. Body mass index, BMI (kg/m2)

    Time frame: 24 weeks

    Changes from baseline to end of study

  3. Body fat content and fat free mass

    Time frame: 24 weeks

    Changes from baseline to end of study

  4. Effect on appetite, hunger and food cravings

    Time frame: 24 weeks

    The Control of Eating Questionnaire (COEQ) is used

  5. Feeling of satiety

    Time frame: 24 weeks

    A 4-point categorical scale is used

  6. Evaluation of the efficacy of Glucosanol by the subjects

    Time frame: 24 weeks

    A 4-point categorical scale is used

  7. Full blood count

    Time frame: 24 weeks

    Done at baseline and end of study

  8. Clinical chemistry parameter

    Time frame: 24 weeks

    Done at baseline and end of study

  9. Blood pressure

    Time frame: 24 weeks

    Measured in mm Hg

  10. Global evaluation of the safety of Glucosanol by the subjects

    Time frame: 24 weeks

    A 4-point categorical scale is used.

  11. Global evaluation of the safety of Glucosanol by the investigators

    Time frame: 24 weeks

    A 4-point categorical scale is used

  12. Occurrence of adverse events

    Time frame: 24 weeks

    All reported adverse events, regardless of causality, will be recorded in the source documents and case report forms

Sponsors and collaborators

Lead sponsor

InQpharm Group

Industry

Registry information

Official study title

Open-label Clinical Investigation to Evaluate the Safety and Efficacy of Glucosanol in Maintaining Body Weight Loss in Overweight and Obese Subjects

Important dates

Study start
2011
Primary completion
2012
Study completion
2012
First posted
Sep 16, 2011
Registry last updated
Jul 27, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.